Library · Metabolic & weight · Weight management and glycemic control
Oral amycretin (NNC0487-0111)
NNC0487-0111, Oral GLP-1/amylin receptor co-agonist
An oral GLP-1 receptor agonist (NNC0487-0111) engineered to survive digestion, aiming to match injectable GLP-1 drugs' benefits for glucose control and weight loss with pill convenience. Still in early clinical testing for type 2 diabetes and obesity, with promising but limited data so far.
Research score 80/100. Reference only, not a dose.
- Appetite Suppression
- Blood Sugar Control
- GLP-1 Agonist
- Metabolic Enhancement
- Gut Health
- US status
- Investigational
- Approval
- Phase 1/2 Clinical Trial
- Evidence
- Oral co-agonist of GLP-1 and Amylin receptors. Demonstrated substantial weight loss (>13% in 12 weeks) in early trials.
- Research score
- 80 / 100
- Indication
- Investigational - Type 2 Diabetes Mellitus
- Origin
- Denmark
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
Activates pancreatic β-cell GLP-1 receptors to drive glucose-dependent insulin release and cut glucagon, while acting on hypothalamic receptors to curb appetite; structural modifications protect it from digestive enzymes.
Safety file
Nausea, vomiting, and diarrhea are frequent, sometimes affecting most users, but typically mild to moderate; no distinct severe risks identified yet.
- Nausea
- Vomiting
- Decreased appetite
- Gastrointestinal discomfort
- Headache